Application progress of temozolomide in clinical tumor chemotherapy

• Main Authors: Cheng ZHONG, Bin WANG, Sheng-qing LV
• Format: Article
• Language: English
• Published: Tianjin Huanhu Hospital 2013-12-01
• Series: Chinese Journal of Contemporary Neurology and Neurosurgery
• Subjects: Glioma; Temozolomide (not in MeSH); Review
• Online Access: http://www.cjcnn.org/index.php/cjcnn/article/view/867
• ISSN: 1672-6731

<p>Temozolomide is an imidazotetrazine derivative of the alkylating agent, which is used to treat central nervous system tumors, especially malignant brain gliomas. It is a milestone in brain giloma chemotherapy. Recently, some researchers used temozolomide for the treatment of other tumors, including melanoma, intracranial metastatic tumors, lymphomas, refractory leukaemia, pituitary tumors, lung cancer, and so on. Some results are encouraging in clinical trials. Here, this paper makes a review on the antineoplastic mechanisms of temozolomide, its indications in gliomas and some unusual indications.</p><p> </p><p>doi：10.3969/j.issn.1672-6731.2013.12.013</p>